Skip to content
13th June 2025

Sustained Disease Control Following Withdrawal of Barzolvolimab in Patients with Chronic Spontaneous Urticaria

1st May 2025

Intraepithelial Mast Cells are Elevated in Active Eosinophilic Esophagitis and Correlate with Eosinophils: Baseline Data from a Randomized Controlled Trial of Barzolvolimab

1st March 2025

Treatment with Barzolvolimab Improves Urticaria Control and Quality of Life in Patients with Chronic Inducible Urticaria: Phase 2 12 Week Results

1st March 2025

Barzolvolimab Improves Urticaria Control and Quality of Life in Patients with Chronic Spontaneous Urticaria: 52-Week Data

1st March 2025

Dual Targeting of Mast Cells and TSLP with the Bispecific Antibody CDX-622

1st February 2025

Dual Inhibition of Mast Cells and Thymic Stromal Lymphopoietin Using a Novel Bispecific Antibody, CDX-622

1st October 2024

Positive Efficacy and Favorable Safety of Barzolvolimab in Chronic Inducible Urticaria: Phase 2 Trial Results

1st September 2024

Barzolvolimab shows profound efficacy and favorable safety over 52 weeks in patients with Chronic Spontaneous Urticaria

1st June 2024

Barzolvolimab Significantly Improves Angioedema in Patients with Chronic Spontaneous Urticaria (CSU): Results from a Phase 2 Trial

1st February 2024

Barzolvolimab Significantly Decreases Chronic Spontaneous Urticaria Disease Activity and is Well Tolerated: Top Line Results from a Phase 2 Trial

Top